Skip to main content

Targeted Therapy For AIDS-related Kaposi's Sarcoma

Angiogenesis plays a critical in the pathogenesis of Kaposi's sarcoma. Platelet derived growth factor (PDGF), vascular endothelial growth factor, fibroblast growth factor and matrix metalloproteinases (MMP) are among the angiogenic pathways that have been implicated in the development of Kaposi's sarcoma. The introduction of specific therapies such as imatinib and Col-3 that target the PDGF pathway and MMPs, respectively, provide a mechanism to test the importance of these pathways in Kaposi's sarcoma in vivo. In this session the rationale for targeted therapy in Kaposi's sarcoma will be discussed. The results from recent trials involving anti-angiogenic agents and signal transduction inhibitors will be reviewed. Additionally, trials of targeted therapies that are underway or in development will be outlined.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Henry Koon.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Koon, H. Targeted Therapy For AIDS-related Kaposi's Sarcoma. Retrovirology 2, S45 (2005). https://doi.org/10.1186/1742-4690-2-S1-S45

Download citation

Keywords

  • Growth Factor
  • Vascular Endothelial Growth Factor
  • Infectious Disease
  • Signal Transduction
  • Cancer Research